In recent years, researchers have also begun to focus on the diagnostic efficacy of mSEPT9 in breast cancer patients, finding that it has higher specificity and lower sensitivity, with diagnostic accuracy slightly superior to that of carcinoembryonic antigen, cancer antigen 153, and cytokeratin 19 (30). This evidence concerns the gene MUC1 and breast cancer.